Qrxpharma (PK) Stock Price - QRXPF

0.00 (0.0%)
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Qrxpharma Ltd (PK) QRXPF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 0.0015 0.00 0.00 0.00 0.0015 16:30:31
Bid Price Ask Price Spread Spread % News
0.0014 1.49 1.49 99.91% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.0015 USD

Qrxpharma (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 112.50k 75.00M 75.00M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
1,000.00 $ - 0.00% - -

more financials information »

Qrxpharma (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical QRXPF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.00150.00150.00150.00154500.000.0%
6 Months0.00220.007070.00150.00293528,931-0.0007-31.82%
1 Year0.00520.051050.00150.007406924,387-0.0037-71.15%
3 Years0.00211.930.00010.006749929,016-0.0006-28.57%
5 Years0.00221.930.00010.006302225,100-0.0007-31.82%

Qrxpharma (PK) Description

QRxPharma Limited is a specialty pharmaceutical company and has been focused on the development and commercialisation of new treatments for pain management and abuse prevention products. The Company's Dual Opioid platform technology is a patented fixed-ratio combination of morphine and oxycodone provides effective analgesia with the potential to decrease clinically important opioid-related side effects, in particular respiratory depression. QRxPharma has four complementary pain management product formulations in late and early stage clinical development including: Moxduo IR, an immediate release oral capsule for acute pain; an abuse deterrent formulation of Moxduo IR, Moxduo CR, a controlled release oral tablet (with abuse deterrent and tamper resistant technologies) for chronic pain; and Moxduo/ IV, an intravenous formulation for moderate to severe hospital-based pain. On 14 August 2014 the Company announced that it is halting all further development work on the Moxduo portfolio of products.

Your Recent History
Qrxpharma ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.